HCT-116 Xenograft Model Service for Colon Cancer

The HCT-116 xenograft model represents one of the most extensively validated and widely adopted preclinical platforms for colon cancer research, enabling robust evaluation of therapeutic efficacy, tumor growth kinetics, and drug response mechanisms in an immunocompromised host environment. Alfa Cytology leverages its deep expertise in preclinical oncology to deliver a fully customizable HCT-116 Xenograft Model Service for Colon Cancer, supporting clients from study design and tumor implantation through endpoint analysis and data reporting, ensuring reproducible, high-quality results tailored to each drug development program.

Overview of HCT-116 Xenograft Model for Colon Cancer

The HCT-116 cell line was originally established in 1979 from a colorectal adenocarcinoma specimen obtained from a 44-year-old male patient. It has since become a cornerstone model in preclinical colon cancer research due to its well-characterized genetic background, rapid proliferation in vitro, and consistent tumorigenicity in immunodeficient mice. The HCT-116 genome has been fully sequenced, and the cell line harbors key oncogenic driver mutations including an activating KRAS G13D mutation, mutant beta-catenin with stabilized protein leading to persistent Wnt signaling activity, and wild-type TP53 and APC. These molecular features closely mirror the genetic landscape observed in a subset of human colorectal cancers, particularly microsatellite instability-high (MSI-H) tumors, making HCT-116 an invaluable tool for investigating tumor biology, signaling pathways, and therapeutic interventions.

In xenograft applications, HCT-116 cells demonstrate robust tumor formation following subcutaneous or orthotopic implantation into immunocompromised mice, with typical tumor doubling times of approximately 6--7 days in untreated controls. The model supports both primary tumor growth studies and metastatic cascade investigations, as HCT-116 cells retain the ability to disseminate to distant organs such as the liver and lungs when introduced via anatomically relevant sites. This versatility has enabled researchers to evaluate sequential combination therapies, study drug administration timing and order effects, and identify novel biomarkers of early treatment response. The reproducibility and adaptability of the HCT-116 xenograft platform continue to make it an indispensable resource for advancing preclinical therapeutic development in colorectal cancer.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting MSI-H colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through KRAS G13D and beta-catenin mutations, and how treatments intersect with Wnt signaling pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. The MTT assay results show Eclipta alba methanol extract (EAME) exhibits specific growth inhibition in colon cancer cells (graph a) as compared to other selected cancer cells (graph panel b, c and d), the results also reveals extract shows negligible toxicity to the normal cell (graph e). Right bottom graph shows relative sensitivities of the cells that were compared by plotting their IC-50 values. (Nelson, Vinod Kumar, et al., 2020)

Cell Line Information: HCT-116

The HCT-116 cell line exhibits epithelial-like cobblestone morphology and grows adherently under standard culture conditions. Its fully sequenced genome, MSI-H status, and key driver mutations make it unique among available colon cancer cell lines and essential for preclinical research targeting microsatellite instability-high colorectal carcinoma.

Our Services

Alfa Cytology offers a comprehensive, end-to-end HCT-116 Xenograft Model Service for Colon Cancer, encompassing tumor cell expansion, quality-controlled inoculation into immunodeficient mice, longitudinal tumor monitoring, treatment administration, and detailed endpoint histopathological and molecular analysis. Our experienced scientific team ensures rigorous study design, real-time data tracking, and customizable reporting formats to accelerate your preclinical drug development pipeline with confidence and precision.

Workflow of HCT-116 Xenograft Model Construction

The construction of a reliable HCT-116 xenograft model follows a standardized, multi-step workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data reproducibility. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Expansion: HCT-116 cells are authenticated via STR profiling and mycoplasma testing prior to expansion. Cells are cultured under optimized conditions to reach the required cell density for implantation, typically 1x10^6 to 5x10^6 cells per injection site.
2. Mouse Strain Selection and Preparation: Immunodeficient mouse strains such as NOD/SCID, nude (nu/nu), or NSG mice are selected based on study objectives. Animals are acclimatized for at least one week, with health monitoring and randomization into treatment groups prior to tumor cell inoculation.
3. Tumor Cell Inoculation: HCT-116 cells are harvested at logarithmic growth phase, resuspended in a 1:1 mixture of serum-free medium and Matrigel or PBS, and injected subcutaneously into the flank or orthotopically into the cecal wall depending on the study design.
4. Tumor Establishment and Monitoring: Tumor growth is monitored by caliper measurements every 2--3 days, with tumor volume calculated using the formula (length x width^2)/2. Tumors typically reach 100--150 mm^3 within 10--14 days post-inoculation, at which point treatment initiation is scheduled.
5. Treatment Administration and Response Monitoring: Test compounds are administered according to the predefined dosing schedule (oral gavage, intraperitoneal, or intravenous). Tumor dimensions and animal body weights are recorded throughout the study period to assess treatment efficacy and general health status.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and photographed. Tissue samples are preserved for histopathology (H&E, IHC), molecular profiling (Western blot, qPCR, RNA-seq), and pharmacokinetic analysis as required by the study protocol.

Figure 2: Schematic workflow illustrating the derivation and construction of the HCT-116 Xenograft Model at Alfa Cytology.

Case Study-HCT-116 Xenograft Model Development

Alfa Cytology has successfully developed and validated the HCT-116 xenograft model for multiple client programs targeting colon cancer therapeutics. In a representative engagement, tumor-bearing mice were established with consistent engraftment rates exceeding 95%, and treatment cohorts demonstrated significant tumor growth inhibition relative to vehicle controls. Detailed pharmacodynamic and pharmacokinetic data, including tumor growth curves, survival analysis, and biomarker expression profiles, are available upon request. For confidentiality reasons, specific quantitative results are not disclosed in this public-facing document; interested parties are encouraged to contact our scientific team to discuss project-specific data and customized study parameters.

Why Choose Alfa Cytology?

Alfa Cytology stands out as a trusted preclinical CRO partner for colon cancer xenograft studies, combining scientific rigor with operational flexibility to meet diverse client needs.

• Verified Cell Line Integrity: Proven expertise in HCT-116 model establishment with high engraftment success rates and reproducible tumor growth kinetics.
• High Take Rates and Consistency: Comprehensive study design support, including power analysis, randomization strategies, and blinded endpoint evaluation to minimize bias.
• Comprehensive Analytical Support: Flexible treatment modalities accommodating oral gavage, intraperitoneal, intravenous, and combination dosing schedules.
• Tailored Study Designs: Integrated endpoint analysis covering histopathology, immunohistochemistry, molecular profiling, and biomarker quantification.
• Standardized Protocols: Real-time data access and transparent communication throughout the study duration, with milestone-based progress reporting.
• Dedicated Project Management: Strict adherence to IACUC guidelines and animal welfare standards, ensuring ethical and compliant preclinical research execution.
• Regulatory Compliance: Customizable reporting formats and raw data packages to facilitate seamless integration into regulatory submission documents.

Contact Us

Ready to accelerate your colon cancer drug development program with a reliable HCT-116 xenograft model? Contact us today to discuss your project requirements, receive a customized study proposal, and explore how Alfa Cytology can support your preclinical research objectives. Our scientific team is available to answer your questions and provide detailed technical guidance---reach out to us and let's advance your therapeutic candidates together. Please reach out to us today via our inquiry form or email to learn more about our HCT-116 Xenograft Model services.

For research use only. Not intended for any clinical use.